Find Dasotraline manufacturers, exporters & distributors on PharmaCompass

Dasotraline

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

DIGITAL CONTENT

6 NEWS #PharmaBuzz

media
6 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 675126-05-3, (1r,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine, (1r,4s)-trans-norsertraline, Norsertraline, (1r,4s)-trans-, Sep-225289, 4d28ey0l5t

Molecular Formula

C₁₆H₁₅Cl₂N

Molecular Weight

292.2 g/mol

InChI Key

SRPXSILJHWNFMK-MEDUHNTESA-N

FDA UNII

4D28EY0L5T

Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and Adult Attention Deficit Hyperactivity Disorder.

1 2D Structure

Dasotraline

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(1R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine

2.1.2 InChI

InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1

2.1.3 InChI Key

SRPXSILJHWNFMK-MEDUHNTESA-N

2.1.4 Canonical SMILES

C1CC(C2=CC=CC=C2C1C3=CC(=C(C=C3)Cl)Cl)N

2.1.5 Isomeric SMILES

C1C[C@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N

2.2 Other Identifiers

2.2.1 UNII

4D28EY0L5T

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine

2.3.2 Depositor-Supplied Synonyms

1. 675126-05-3

2. (1r,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine

3. (1r,4s)-trans-norsertraline

4. Norsertraline, (1r,4s)-trans-

5. Sep-225289

6. 4d28ey0l5t

7. Dasotraline [usan:inn]

8. Unii-4d28ey0l5t

9. Dasotraline [inn]

10. Dasotraline (usan/inn)

11. Dasotraline [usan]

12. Dasotraline [who-dd]

13. Schembl263142

14. Dasotraline(sep-225289)

15. Dasotraline; Sep 225289

16. Gtpl8308

17. Chembl3301595

18. Dtxsid20217855

19. Bcp24754

20. Ex-a2622

21. Zinc2510873

22. Dasotraline(sep-225289) Free Base

23. Db12305

24. Sep-225,289

25. Ac-36184

26. Hy-12850

27. Cs-0012724

28. D10700

29. A857937

30. Q27076989

31. (1r,4s)-4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphthalen-1-ylamine

32. 4beta-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalene-1alpha-amine

33. 1-naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-, (1r,4s)-

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₁₆H₁₅Cl₂N
Molecular Weight	292.2 g/mol
XLogP3	4.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	1
Rotatable Bond Count	1
Exact Mass	291.0581549 g/mol
Monoisotopic Mass	291.0581549 g/mol
Topological Polar Surface Area	26 Å²
Heavy Atom Count	19
Formal Charge	0
Complexity	309
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 Mechanism of Action

Dasotraline has been shown in preclinical studies to be a potent and balanced reuptake inhibitor of serotonin, norepinephrine and dopamine (SNDRI). Serotonin, norepinephrine and dopamine are neurotransmitters associated with depression. There are currently no marketed treatments for depression that inhibit reuptake of all three neurotransmitters.

Drugs in Development